Determinants of the Timing of Symptomatic Treatment in Early Parkinson Disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.

PDF's targeted PubMed search provides you with access to journal articles from the last 90 days that may be pertinent to Parkinson's disease research. 

Not what you're looking for? Do you need informational publications about Parkinson's targeted for people living with Parkinson's, caregivers and family members?  Please browse PDF's educational materials and programs - which are all available electronically or in print.  Order for yourself, a loved one or in bulk for your patients or support group.

Arch Neurol 2009 Jul;

Authors: Sotirios A Parashos, Christopher J Swearingen, Kevin M Biglan, Ivan Bodis-Wollner, Grace S Liang, G Webster Ross, Barbara C Tilley, Lisa M Shulman,

Golden Valley, Minnesota (Dr Parashos); Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, Charleston (Mr Swearingen and Dr Tilley); Department of Neurology, University of Rochester, Rochester, New York (Dr Biglan); State University of New York, Downstate Medical Center, Brooklyn (Dr Bodis-Wollner); The Parkinson's Institute and Clinical Center, Sunnyvale, California (Dr Liang); Pacific Health Research Institute, Honolulu, Hawaii (Dr Ross); and Department of Neurology, University of Maryland School of Medicine, Baltimore (Dr Shulman).

OBJECTIVE: To assess the predictive value of baseline measures of impairment, disability, and quality of life for the timing of initiation of symptomatic treatment in early Parkinson disease (PD). DESIGN: Inception cohort analysis. SETTING: Ambulatory population from multiple sites in the United States and Canada. PARTICIPANTS: Four hundred thirteen patients with early, untreated PD who participated in 2 double-blind trials that assessed the potential of experimental drugs to serve as disease-modifying agents in PD.Intervention Participants were randomized into treatment groups: creatine (n = 67), minocycline (n = 66), coenzyme Q10 (n = 71), GPI-1485 (n = 71), and placebo (n = 138).Main Outcome Measure Time between baseline assessment and need for the initiation of symptomatic treatment for PD. The following baseline variables were assessed for their relation to the main outcome measure, while adjusting for possible treatment effect: sex; age; level of education; race/ethnicity; disease duration; occupational status; and Unified Parkinson Disease Rating Scale (UPDRS), Medical Outcomes Study Short Form Survey, Modified Rankin Scale, Schwab and England Activities of Daily Living Scale, Total Functional Capacity Scale, 39-item Parkinson Disease Questionnaire, and Geriatric Depression Scale scores. Variables reaching statistical threshold in univariate analyses (alpha = .15) were entered into a multivariable Cox proportional hazards regression model using time to symptomatic treatment as the dependent variable. RESULTS: Approximately half (48.5%) of the participants reached end point within 12 months. Higher baseline impairment and disability, as determined by UPDRS III (motor section), UPDRS II (activities of daily living section, participant rating), and Modified Rankin Scale scores and level of education were independently associated with an earlier need for symptomatic treatment. CONCLUSIONS: In early PD, greater impairment and disability and higher level of education are independently associated with an earlier need for symptomatic treatment.Published online July 13, 2009 (doi:10.1001/archneurol.2009.159).

PMID: 19597081 [PubMed - as supplied by publisher]

See More

Back to PubMed Articles